GlassScriptPhysician profile
Jeffrey L Zonderman
NPI 1649206053
$10,584.87
in general payments reported to CMS, 2019-2025
25 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $486 · 2021: $765 · 2022: $1,140 · 2023: $1,443 · 2024: $2,692 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,441.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,895.20 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Astellas Pharma US INC | $1,804.65 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $1,281.66 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $985.50 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Tarsus Pharmaceuticals, INC. | $713.27 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $708.57 | 2019-2021 | |
| Glaukos Corporation | $531.04 | 2024-2025 | Idosetr, Idose |
| Allergan, INC. | $523.54 | 2019-2021 | |
| Oyster Point Pharma, INC. | $518.02 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $469.44 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $231.13 | 2021-2025 | Cequa |
| Horizon Therapeutics Plc | $167.34 | 2022-2023 | Tepezza |
| Biotissue Holdings INC. | $149.72 | 2020-2025 | |
| Dompe US, INC. | $118.56 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $99.64 | 2022-2025 | Dextenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $80.75 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $78.88 | 2020-2025 | Koselugo |
| Kala Pharmaceuticals, INC. | $63.83 | 2021 | |
| Thea Pharma INC. | $40.73 | 2022-2023 | |
| Harrow Eye, LLC | $28.77 | 2024 | Vevye |
| Coherus Oncology, INC. | $24.58 | 2023 | |
| Recordati_rare_diseases_inc. | $23.53 | 2024 | Cystadrops |
| Amgen INC. | $20.00 | 2025 | Tepezza |
| Coopervision INC. | $13.46 | 2025 | Myday Contact Lens |
| Shire North American Group INC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Zonderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.